rs180177097
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024675.4(PALB2):c.1027C>T(p.Gln343*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_024675.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial cancer of breast Pathogenic:4
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
- -
This sequence change creates a premature translational stop signal (p.Gln343*) in the PALB2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 17200671, 17200672, 24136930, 25099575). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 21184274, 24556926, 27624329). It is commonly reported in individuals of Italian ancestry (PMID: 21184274, 24556926, 27624329). ClinVar contains an entry for this variant (Variation ID: 126583). For these reasons, this variant has been classified as Pathogenic. -
PVS1, PS4_STR, PM2_SUP, PP1 -
not provided Pathogenic:2
Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Marc Tischkowitz. -
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 36278678, 17200668, 17200672, 17200671, 24136930, 33573335, 27624329, 25099575, 21184274, 24556926) -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant changes 1 nucleotide in exon 4 of the PALB2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in at least one individual affected with breast cancer and as a recurrent mutation in Italian hereditary breast and ovarian cancer families (PMID: 21184274, 24556926, 25099575, 33471991; Leiden Open Variation Database DB-ID PALB2_010060). A haplotype analysis suggests that this variant may be a founder mutation among hereditary breast and ovarian cancer families of Italian ancestry (PMID: 27624329). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of PALB2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The p.Q343* pathogenic mutation (also known as c.1027C>T), located in coding exon 4 of the PALB2 gene, results from a C to T substitution at nucleotide position 1027. This changes the amino acid from a glutamine to a stop codon within coding exon 4. This mutation has been reported in a breast and pancreatic cancer family as well as in multiple breast cancer families in the literature (Peterlongo P et al. Breast Cancer Res. Treat. 2011 Apr;126:825-8; Catucci I et al. Genet. Med. 2014 Sep;16:688-94; Antoniou AC et al. N. Engl. J. Med. 2014 Aug;371:497-506). Furthermore, haplotype analysis has indicated that c.1027C>T is an Italian founder mutation (Catucci I et al. Breast Cancer Res. Treat. 2016 Nov;160:121-129). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Hereditary breast ovarian cancer syndrome Pathogenic:1
- -
Breast-ovarian cancer, familial, susceptibility to, 5 Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at